rs234709 — CBS

Intronic CBS variant that tags the CBS locus in GWAS studies; associated with altered homocysteine metabolism capacity and one-carbon methylation efficiency

See your personal result for CBS

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

CBS Intron Variant — A Locus Tag for Transsulfuration Pathway Capacity

The CBS gene encodes [cystathionine beta-synthase | the enzyme that commits homocysteine to the transsulfuration pathway, converting it to cystathionine, then cysteine, then glutathione], a vitamin B6-dependent enzyme located on chromosome 21. CBS sits at the critical junction where the methylation and transsulfuration pathways diverge: it irreversibly diverts homocysteine away from the methylation cycle and toward cysteine and [glutathione | the body's most abundant antioxidant, synthesized from cysteine via glutamate and glycine] synthesis. rs234709 is an intronic variant within CBS — it does not change the protein sequence, but it tags the CBS locus in population genetics studies and captures variation in CBS expression and enzyme activity across the haplotype block.

The Mechanism

rs234709 sits in intron 5 of the CBS gene on the minus strand of chromosome 21 (GRCh38 position chr21:43,066,854, C>T on the plus strand). As an intronic variant, it does not directly alter the CBS protein. However, [intronic variants in regulatory introns can influence mRNA splicing, stability, or transcription factor binding | affecting how much protein is produced, not its sequence], and rs234709 is in [linkage disequilibrium | LD; the tendency of nearby genetic variants to be inherited together as a haplotype block] with the functional CBS C699T variant (rs234706, r²=0.69). This means the T allele at rs234709 predominantly co-occurs with the common C allele of CBS C699T — the haplotype associated with lower CBS enzyme efficiency — rather than with the protective T allele of C699T. CBS requires [pyridoxal-5-phosphate (PLP) | the active form of vitamin B6] as an essential cofactor and is allosterically activated by [S-adenosylmethionine (SAMe) | the universal methyl donor in the cell, linking CBS activity to methionine availability]. When CBS activity is reduced, homocysteine accumulates in plasma and tissues. Elevated homocysteine impairs nitric oxide synthase activity, promotes oxidative stress, and increases cardiovascular and neurological risk. The enzyme also generates [hydrogen sulfide (H₂S) | a gaseous signaling molecule with vasodilatory, cytoprotective, and anti-inflammatory properties] as a byproduct of CBS-catalyzed reactions. Variants in CBS affecting enzyme expression thus have downstream effects not just on homocysteine clearance and glutathione synthesis, but also on H₂S production — a connection explored in sepsis research.

The Evidence

The strongest evidence for rs234709 comes from a study of 142 arsenic-exposed individuals in Argentina11 142 arsenic-exposed individuals in Argentina
Porter et al., Environmental Research, 2010. The T allele was associated with a 24% increase in monomethylarsonic acid (%MMA) excretion (from 14.4% to 18.8%), alongside a 7% decrease in dimethylarsenic. This finding is mechanistically informative: arsenic methylation is driven by the same one-carbon pool (SAMe) that CBS competes with, and reduced CBS efficiency is expected to impair the SAMe-dependent methylation of arsenic. The T allele association with worse arsenic methylation is consistent with the T allele tagging a reduced-activity CBS haplotype. A 2014 GWAS meta-analysis22 2014 GWAS meta-analysis
Williams et al., PLOS Genetics, 2014 of homocysteine and methionine metabolism in large European cohorts identified the CBS locus — including rs234709 — as one of five major genetic determinants of plasma homocysteine concentrations. CBS polymorphisms collectively explained a portion of the homocysteine variance at genome-wide significance (p = 3.15×10⁻²⁶). A Mendelian randomization analysis33 Mendelian randomization analysis using 13 homocysteine-associated loci (including CBS) found that genetically elevated homocysteine was NOT associated with coronary artery disease risk in white populations, refuting the causal relevance of moderately elevated homocysteine despite its established observational correlation with CVD. A Chinese sib-pair study44 Chinese sib-pair study
Sun et al., Journal of Thrombosis and Thrombolysis, 2017 examined CBS rs2851391 (in the same CBS locus as rs234709) alongside other one-carbon metabolism SNPs in relation to carotid intima-media thickness (CIMT), a measure of subclinical atherosclerosis. The CBS locus showed associations with CIMT through interaction effects with other one-carbon metabolism genes. A European study identified CBS gene variants as associated with susceptibility to sepsis55 susceptibility to sepsis
Sponholz et al., European Journal of Human Genetics, 2016, linking CBS-dependent H₂S production to sepsis susceptibility — a distinct mechanism from homocysteine that highlights the breadth of CBS's physiological role.

Practical Actions

The T allele at rs234709 tags a haplotype background associated with lower CBS enzyme efficiency. In practical terms, this means a modestly reduced capacity to: (1) clear homocysteine via transsulfuration, (2) produce cysteine for glutathione synthesis, and (3) generate cytoprotective H₂S. These effects are subtle compared to pathogenic CBS mutations that cause homocystinuria, but they are relevant when combined with other methylation pathway variants (particularly MTHFR) or when dietary B vitamin status is marginal. The primary intervention is ensuring optimal cofactor availability. CBS is directly dependent on vitamin B6 (as PLP), and the broader methylation cycle requires folate and B12. Using the active forms of these vitamins — methylfolate (5-MTHF) rather than folic acid, methylcobalamin rather than cyanocobalamin, and P5P rather than pyridoxine — bypasses enzymatic conversion steps that may be impaired by other genetic variants.

Interactions

rs234709 is in linkage disequilibrium with rs234706 (CBS C699T, r²=0.69) — the two variants are co-inherited as part of the CBS haplotype block. Because they are not in perfect LD, however, they capture partially overlapping but distinct variation, and both are included in our database to capture the full CBS locus. The most clinically important interaction is with MTHFR (rs1801133 C677T and rs1801131 A1298C). Reduced MTHFR activity causes homocysteine accumulation upstream, and when CBS efficiency is also reduced (as suggested by the T allele at rs234709), there is less capacity to reroute the excess homocysteine through transsulfuration. This double impairment — reduced remethylation and reduced transsulfuration — can meaningfully elevate plasma homocysteine and increase cardiovascular risk. Individuals carrying both MTHFR risk alleles and the CBS rs234709 T allele should prioritize measuring plasma homocysteine and ensuring all methylation cofactors are optimal.

Nutrient Interactions

folate increased_need
vitamin B6 increased_need
vitamin B12 increased_need

Genotype Interpretations

What each possible genotype means for this variant.

CC Standard CBS Expression Normal

Common genotype associated with typical transsulfuration pathway capacity

You have two copies of the C allele, the reference allele at this position. This is found in approximately 32% of people of European descent. The C allele at rs234709 is on the same haplotype as the protective T allele of CBS C699T (rs234706), suggesting adequate CBS enzyme expression and transsulfuration activity. Your capacity to clear homocysteine and produce cysteine and glutathione through this pathway is not impaired by this variant.

CT Intermediate CBS Expression Intermediate

One copy of the variant associated with modestly reduced transsulfuration capacity

The CT genotype places you in the majority of the population. The effect of one T allele on CBS expression is subtle and does not typically produce abnormal homocysteine levels in isolation. The T allele at rs234709 co-occurs predominantly with the common (non-protective) C allele at CBS C699T (rs234706) in the same haplotype block, meaning you have a standard rather than enhanced transsulfuration capacity from this locus. The main practical concern is ensuring adequate vitamin B6 for CBS enzyme activity and adequate folate/B12 for the upstream remethylation pathway. The compound interaction with other methylation pathway variants is handled by the combined variant analysis.

TT Reduced CBS Expression Reduced

Two copies of the variant associated with reduced CBS transsulfuration capacity and altered methylation efficiency

The TT genotype represents the lowest-activity CBS haplotype at this locus. CBS is the gatekeeper of the transsulfuration pathway: when its expression or activity is reduced, homocysteine accumulates, cysteine production decreases, and the capacity to synthesize glutathione — the body's primary antioxidant — is constrained. The CBS enzyme also generates hydrogen sulfide (H₂S), a cytoprotective gaseous signaling molecule; reduced CBS activity may lower H₂S production, which has been linked to increased inflammatory responses. In isolation, this variant does not cause the severe hyperhomocysteinemia seen in CBS-deficiency disease (homocystinuria). However, in combination with reduced MTHFR activity (from MTHFR C677T or A1298C variants), the combined burden on homocysteine clearance — both the remethylation and transsulfuration routes — can produce clinically significant homocysteine elevation and corresponding cardiovascular and neurological risk. The finding from the arsenic study (PMID 20670920) is mechanistically important: the same SAMe pool that methylates arsenic also methylates homocysteine, DNA, and neurotransmitters. A 24% reduction in SAMe-dependent methylation capacity is a functional signal, not just a surrogate marker.